Bio-Path Holdings
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Bio-Path Holdings sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Bio-Path Holdings: 5 sponsored US clinical trials, 3 recruiting.
Bio-Path Holdings sponsors 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Peripheral T-cell Lymphoma (PTCL), with 1 trials.
Upper-quartile sponsor footprint
Bio-Path Holdings sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
NCT04196257
A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
NCT05190471
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
NCT02781883
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
NCT04072458
Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS
NCT01159028
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
What is open in the Bio-Path Holdings pipeline
3 recruiting of 5 indexed (60% open); 1 completed (20%).
Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Peripheral T-cell Lymphoma (PTCL) (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Bio-Path Holdings: open-pipeline peers nationwide
Peers matched on 5 registered trials and 60% open enrollment, not the therapeutic-area sidebar.
Bio-Path Holdings sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 60% open enrollment (± trial volume)
- Alaska Native Tribal Health Consortium · 60% recruiting · 5 trials
- Anwaar Saeed · 60% recruiting · 5 trials
- Autolus Limited · 60% recruiting · 5 trials
- Beam Therapeutics · 60% recruiting · 5 trials
Related
What to do with this Bio-Path Holdings page
5 registered trials is a research-attention snapshot, not an endorsement of Bio-Path Holdings or any single study.
- 3 of Bio-Path Holdings's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Peripheral T-cell Lymphoma (PTCL) is the condition Bio-Path Holdings studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Peripheral T-cell Lymphoma (PTCL) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Bio-Path Holdings pipeline card: 5 registered trials from official public datasets.Report a data error.